COAG Hemab Therapeutics Holdings, Inc. - Common Stock
$50,39
Harga · Agu 20, 2026
Fundamental per Agu 11, 2026
Rentang 52M
$23–$55
84% of range
Peringkat Analis
BUY
11 analysts
Target Harga
$61
+21% upside
P/E (TTM)
—
ROE
—
Margin Laba Bersih
—
COAG Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$50.39
Kapitalisasi Pasar
—
P/E (TTM)
—
EPS (TTM)
—
Pendapatan (TTM)
—
Imbal Hasil Dividen
—
ROE
—
D/E Utang/Ekuitas
—
Rentang 52M
$23 – $55
COAG Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
—
EPS
—
Arus Kas Bebas
—
Margin
—
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
COAG
Median Rekan
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
COAG
Median Rekan
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
COAG
Median Rekan
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
COAG
Median Rekan
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
COAG
Median Rekan
COAG Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
BELI
11 analis
- Beli Kuat 4 36,4%
- Beli 6 54,5%
- Tahan 1 9,1%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
5 analis · 2026-08-18
Median
$60.00
Rata-rata
$61.20
← Di bawah semua target
$50.39
Rendah
$58.00
Tinggi
$65.00
Target median
$60.00
+19,1%
Target rata-rata
$61.20
+21,5%
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| COAG | — | — | — | — | — | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| MLYS | $2.96B | -15.8 | — | — | -32.2% | — |
| KLRA | — | — | — | — | — | — |
| VERA | — | -10.9 | — | — | -55.9% | — |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| ADMA | $4.34B | 30.4 | 19.6% | 28.8% | 33.6% | 57.4% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Neraca 21
| Metrik | Tren | 2025 |
|---|---|---|
| Cash & Equivalents | $88M | |
| Short-term Investments | $98M | |
| Prepaid Expense | $7M | |
| Current Assets | $193M | |
| PP&E (Net) | $609.0K | |
| PP&E (Gross) | $1M | |
| Accum. Depreciation | $723.0K | |
| Other Non-current Assets | $531.0K | |
| Total Assets | $195M | |
| Accounts Payable | $6M | |
| Accrued Liabilities | $4M | |
| Current Liabilities | $11M | |
| Capital Leases | $573.0K | |
| Total Liabilities | $11M | |
| Common Stock | $0 | |
| Paid-in Capital | $5M | |
| Retained Earnings | $-182M | |
| AOCI | $175.0K | |
| Stockholders' Equity | $-177M | |
| Liabilities + Equity | $195M | |
| Shares Outstanding | 0 |
Laporan Laba Rugi 12
| Metrik | Tren | Q2 2026 | Q1 2026 |
|---|---|---|---|
| R&D Expense | $20M | $19M | |
| SG&A Expense | $6M | $4M | |
| Operating Expenses | $26M | $24M | |
| Operating Income | $-26M | $-24M | |
| Pretax Income | $-24M | $-23M | |
| Income Tax | $97.0K | $12.0K | |
| Net Income | $-24M | $-23M | |
| EPS (Basic) | $-0.80 | $-23.98 | |
| EPS (Diluted) | $-0.80 | $-23.98 | |
| Shares (Basic) | 30,111,338 | 946,000 | |
| Shares (Diluted) | 30,111,338 | 946,000 | |
| EBITDA | $-26M | $-24M |
Neraca 21
| Metrik | Tren | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Cash & Equivalents | $237M | $50M | |
| Short-term Investments | $220M | $114M | |
| Prepaid Expense | $7M | $6M | |
| Current Assets | $464M | $169M | |
| PP&E (Net) | $596.0K | $648.0K | |
| PP&E (Gross) | $1M | $1M | |
| Accum. Depreciation | $871.0K | $796.0K | |
| Other Non-current Assets | $2M | $4M | |
| Total Assets | $468M | $175M | |
| Accounts Payable | $6M | $6M | |
| Accrued Liabilities | $6M | $7M | |
| Current Liabilities | $13M | $13M | |
| Capital Leases | $566.0K | $519.0K | |
| Total Liabilities | $14M | $14M | |
| Common Stock | $5.0K | $0 | |
| Paid-in Capital | $686M | $6M | |
| Retained Earnings | $-229M | $-205M | |
| AOCI | $-3M | $-439.0K | |
| Stockholders' Equity | $454M | $-199M | |
| Liabilities + Equity | $468M | $175M | |
| Shares Outstanding | 46,705,410 | 946,000 |
Arus Kas 8
| Metrik | Tren | Q2 2026 | Q1 2026 |
|---|---|---|---|
| D&A | $75.0K | $73.0K | |
| Other Non-cash | · | $1M | |
| Operating Cash Flow | $-23M | $-22M | |
| CapEx | $23.0K | $112.0K | |
| Investing Cash Flow | $-107M | $-16M | |
| Financing Cash Flow | $318M | $-460.0K | |
| Net Change in Cash | $188M | $-38M | |
| Free Cash Flow | · | $-22M |
Profitabilitas 3
| Metrik | Tren | Q2 2026 | Q1 2026 |
|---|---|---|---|
| ROA | -10.3% | -25.9% | |
| ROE | -10.6% | 22.8% | |
| ROIC | -5.8% | 11.9% |
Likuiditas & Solvabilitas 2
| Metrik | Tren | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Current Ratio | 35.8 | 12.8 | |
| Quick Ratio | 35.3 | 12.4 |
Valuasi (TTM) 3
| Metrik | Tren | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Market Cap | $1.72B | · | |
| P/B | 3.8 | · | |
| P / Tangible Book | 3.8 | · |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Orang dalam perusahaan 4 orang dalam · 2 pejabat · 1 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Mads Nikolaj Behrndt-Eriksen | Chief Financial Officer and General Manager | 30 April 2026 A | — | 0 | 0 | $0 |
| Catherine Madigan | Chief Medical Officer | 30 April 2026 A | — | 0 | 0 | $0 |
| John Maraganore | Direktur | 4 Mei 2026 C | 35.948 | 0 | 0 | $0 |
| Novo Holdings A/S | — | 4 Mei 2026 C | 4.180.550 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 1 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| AI DEN-MAB LLC, Access Industries Holdings LLC, AI Biotechnology LLC, Access Industries Management LLC, Len Blavatnik | 11 Mei 2026 | 10,40% | Pengajuan awal | Investasi pasif | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 6 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | — | — | 15 Juli 2026 | Harian |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 Juli 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Juli 2026 | Harian |
| VTWV · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Juli 2026 | Harian |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Juli 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Juli 2026 | Harian |